The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study

BACKGROUND: The development of chemotherapy and treatment strategies for metastatic colorectal cancer (mCRC) have provided patients with significant survival benefits. Currently, molecular targeting agents and late‐line treatment with regorafenib and trifluridine/tipiracil (FTD/TPI) are available. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakami, Takeshi, Masuishi, Toshiki, Kawamoto, Yasuyuki, Go, Hirofumi, Kato, Kyoko, Kumanishi, Ryosuke, Sawada, Kentaro, Yuki, Satoshi, Yamamoto, Kouji, Komatsu, Yoshito, Muro, Kei, Fushiki, Kunihiro, Shirasu, Hiromichi, Yamazaki, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160807/
https://www.ncbi.nlm.nih.gov/pubmed/35182029
http://dx.doi.org/10.1002/cam4.4599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160807/
https://www.ncbi.nlm.nih.gov/pubmed/35182029
http://dx.doi.org/10.1002/cam4.4599

Ejemplares similares